Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

2.95
-0.1850-5.91%
Volume:431.70K
Turnover:1.34M
Market Cap:97.77M
PE:-0.95
High:3.33
Open:3.08
Low:2.94
Close:3.13
Loading ...

Company Profile

Company Name:
Lexeo Therapeutics
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
- -
Office Location:
345 Park Avenue South,6th Floor,New York,New York,United States
Zip Code:
10010
Fax:
- -
Introduction:
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Directors

Name
Position
R. Nolan Townsend
Chief Executive Officer and Director
Steven Altschuler
Chairman of the Board
Bernard Davitian
Director
Brenda Cooperstone
Director
Mette Kirstine Agger
Director
Paula HJ Cholmondeley
Director
Reinaldo Diaz
Director

Shareholders

Name
Position
R. Nolan Townsend
Chief Executive Officer and Director
Eric Adler
Chief Scientific Officer
Jenny R. Robertson
Chief Legal and Administrative Officer
Paul McCormac
Chief Technical Officer